Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | NCF1 | P14598 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845135 | 0.83 | OPRK1 (0.38) | PIK3CDHRH4OPRK1ALDH1A1 | |
| SCHEMBL2113711 | 0.81 | OPRK1 (0.38) | PIK3CDNCF1ABCG2HRH4OPRK1 | |
| SCHEMBL2113713 | 0.81 | OPRK1 (0.38) | PIK3CDNCF1ABCG2HRH4OPRK1 | |
| SCHEMBL14481792 | 0.77 | OPRK1 (0.39) | PIK3CDNCF1ABCG2OPRK1CNR2 | |
| SCHEMBL2115419 | 0.76 | PIK3CD (0.44) | PIK3CDABCG2DPP4CNR2ALDH1A1 | |
| SCHEMBL2113761 | 0.76 | PIK3CD (0.43) | PIK3CDABCG2OPRK1CNR2GFER | |
| SCHEMBL2117490 | 0.72 | OPRK1 (0.38) | HRH4OPRK1ALDH1A1 | |
| SCHEMBL2117487 | 0.72 | OPRK1 (0.38) | HRH4OPRK1ALDH1A1 | |
| SCHEMBL14481093 | 0.72 | HPGD (0.39) | OPRK1 | |
| SCHEMBL14481092 | 0.72 | HPGD (0.39) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PIK3CD 6/4885NCF1 2116/4885ABCG2 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.